arrow
H

Hiroaki Iwamoto

Kanazawa University
H指数:28
被引数:2,614

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association Between Castration-resistant Prostate Cancer Progression Patterns and Survival Outcomes in Metastatic Castration-sensitive Prostate Cancer: A Post Hoc Analysis of the TITAN Trial

去势抵抗性前列腺癌进展模式与转移性去势敏感性前列腺癌患者生存结局的关联:TITAN试验的事后分析

2026-09-120
OA
Triplet Therapy (Androgen Deprivation Therapy

三联疗法(雄激素剥夺疗法

2026-07-150
PRE
Fibroblast-mediated KRAS activation in double-negative prostate cancer

成纤维细胞介导的KRAS激活在双阴性前列腺癌中的作用

2026-05-020
OAAI
High-Dose-Rate Brachytherapy Combined with External Beam Radiotherapy for Newly Defined Very High-Risk and Regional Prostate Cancer: A 17-Year Single-Institution Experience

高剂量率近距离治疗联合外照射放疗治疗新定义的极高危和区域前列腺癌:一项17年单机构经验

Cancers
IF4.4
2026-04-170
OA
Dynamic Changes in Albumin and Systemic Immune-Inflammation Index as Prognostic Markers in Patients Treated with Cabozantinib After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

白蛋白和全身免疫炎症指数的动态变化作为接受免疫检查点抑制剂治疗后使用卡博赞尼治疗转移性肾细胞癌患者的预后标志物

2025-12-110
OAAI
Whole-Blood RNA Expression of Immunosuppressive Cell-Related Genes Is Associated With Prostate Cancer Progression

免疫抑制细胞相关基因的全血RNA表达与前列腺癌进展相关

2025-12-010
PRE
Real-World Efficacy of Postoperative Adjuvant Nivolumab in High-Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population

高危尿路上皮癌术后辅助纳武利尤单抗的疗效:一项亚洲人群的回顾性比较研究

2025-11-010
PRE
Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer

高强度率近距离放射治疗后七年内前列腺特异性抗原(PSA)≤0.2 ng/mL表明符合停止前列腺特异性抗原监测的条件,用于前列腺癌。

2025-09-280
OAAI
Androgen Receptor-Controlled microRNA-124-3p.2 Suppresses Prostate Cancer Progression via CCL2 Inhibition

雄激素受体调控的microRNA-124-3p.2通过抑制CCL2抑制前列腺癌进展。

2025-07-220
OAAI
Tumor-associated macrophages promote bladder cancer metastasis through the CCL20-CCR6 axis

肿瘤相关巨噬细胞通过CCL20-CCR6轴促进膀胱癌转移

2025-02-010
OAAI